TrialBritish journal of cancer2016

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.

Anne Ørbo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.